HAE Flare Management and Monitoring

Written by Margaret Anne Rockwood | Last updated September 9th, 2026
Medically reviewed by Timothy J. Craig, DO

Individuals diagnosed with hereditary angioedema (HAE) typically experience unpredictable, recurrent attacks that vary considerably in frequency, severity, and anatomic location. Even patients with relatively infrequent attacks remain at risk for life-threatening laryngeal edema, underscoring the importance of comprehensive disease management.

Current guidelines from the World Allergy Organization (WAO), European Academy of Allergy and Clinical Immunology (EAACI), and the US Hereditary Angioedema Association (HAEA) emphasize that clinicians should regularly assess disease burden, treatment response, and health-related quality of life (QoL) to help guide flare management.

Check on Attack Frequency and Triggers

Attack frequency varies substantially both among individuals and within an individual’s lifetime. For some, attacks occur only once or twice a year, while others have multiple attacks each month or even weekly episodes, still others have no attacks. At the individual patient level, this can wax and wane for various reasons.

Although many attacks occur without an identifiable precipitating factor, patients commonly report recognizable triggers. Frequently reported triggers include:

• emotional stress
• minor trauma
• dental procedures
• surgery
• upper respiratory infections
• estrogen-containing contraceptives or hormone replacement therapy
• hormonal changes, including menstruation and pregnancy
• angiotensin-converting enzyme (ACE) inhibitors
• prolonged pressure or repetitive physical activity

While many patients may be unable to identify a consistent trigger for every attack, efforts should be made to identify each patient’s precipitating factors. Despite the most assiduous avoidance of triggers, however, attacks can occur spontaneously. Importantly, disease severity is not solely determined by attack frequency, as patients with otherwise mild disease remain susceptible to severe abdominal or laryngeal attacks.

Several tools may help patients track their triggers and attacks, such as:

• paper diaries describing attacks
• smartphone symptom-tracking applications
• electronic treatment logs
• calendar-based attack records
• manufacturer-sponsored digital patient support programs

Patients should be encouraged to record:

• date and location of each attack
• suspected trigger
• severity
• medication used
• time from symptom onset to treatment
• time to symptom resolution

These records can help identify patterns, evaluate treatment response, and support insurance authorization for prophylactic therapies.

Monitor Attack Severity & Disease Burden

Routine monitoring allows clinicians to assess disease activity, control, and treatment effectiveness, and identify patients who may benefit from changes in therapy.

At each follow-up visit, physicians should document:

• number of attacks since the previous visit
• attack site location(s)
• attack severity
• duration of attacks
• time to treatment after symptom onset
• response to on-demand therapy
• emergency department (ED) visits and/or hospitalizations
• missed work or school
• need for caregiver assistance

Laryngeal attacks, ED utilization, or increasing attack frequency warrant prompt reassessment of the treatment plan.

Attack frequency alone does not fully reflect disease burden. Patients with relatively few attacks may still experience significant anxiety, reduced productivity, or avoidance of travel and social activities because of fear of unpredictable episodes.

Routine assessment should include discussion of:

• ability to work or attend school
• physical activity limitations
• sleep disruption
• anxiety related to future attacks
• travel restrictions
• family and caregiver burden

Several tools can help guide decision-making, including the Angioedema Activity Score (AAS) for disease activity, the Angioedema Control Test (AECT) for disease control, and quality-of-life instruments such as the AE-QoL and HAE-QoL.

Ask Key Questions at Follow-up Visits

Routine follow-up visits provide an opportunity to identify changes in disease activity that may not be apparent from attack counts alone.

Disease Activity

• How many attacks have you experienced since your last visit?
• Have attacks become more severe or lasted longer?
• Have you experienced any facial or throat swelling?

Treatment Response

• Did you have access to your rescue medication when needed?
• How quickly were you able to administer treatment?
• Did your medication reliably control symptoms?
• Have you required repeat dosing?

Quality of Life

• Have attacks interfered with work, school, or family responsibilities?
• Have you avoided travel or social activities because of HAE?
• Are you satisfied with your current treatment plan?

Safety

• Have you visited the emergency department?
• Have you required hospitalization?
• Have you experienced medication-related adverse effects?

Groups such as the US HAEA Medical Advisory Board recommend individualized follow-up intervals based on disease activity and treatment status. In general:

• Newly diagnosed patients should be evaluated at intervals of about every 3 months until disease control is established.
• Patients receiving long-term prophylaxis should undergo periodic reassessment of efficacy, adverse effects, and adherence.
• Stable patients may be followed every 6 to 12 months, with earlier evaluation following significant changes in disease activity or treatment.

Regular monitoring can help physicians identify changes in disease activity and optimize therapy over time.

Educate Patients on Emergency Preparedness

Every patient with HAE should have an individualized emergency action plan. Physicians can encourage patients to:

• Carry enough on-demand medication to treat at least 2 attacks.
• Consider wearing medical identification that they have HAE and what to do in case of severe presentation.
• Maintain a written emergency treatment plan and inform family members, caregivers, and schools or employers about emergency treatment procedures
• Seek immediate emergency evaluation for any symptoms suggesting laryngeal involvement, even after self-treatment.
• Provide emergency department personnel with a disease-specific treatment letter, which may speed up appropriate treatment.
• Explore an HAE association app that includes care and treatment of HAE.

Sources

• Banerji A, Davis KH, Brown TM, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600-607. doi:10.1016/j.anai.2020.02.003
• Betschel S, et al. The International/Canadian hereditary angioedema guideline. 2025/2026 update.
• Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161(5):1153-1158. doi:10.1111/j.1365-2133.2009.09353.x
• Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046
• Caballero T, Prior N. Burden of illness and quality-of-life measures in angioedema conditions. Immunol Allergy Clin North Am. 2017;37(3):597-616. doi:10.1016/j.iac.2017.04.005
• Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214
• A treat-to-target approach in hereditary angioedema: expert consensus from a European committee. Front Immunol. 2026.
• Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013;68(9):1185-1192. doi:10.1111/all.12209
• Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67(10):1289-1298. doi:10.1111/all.12007
• Vázquez DO, Giavina-Bianchi P, Josviack D, et al. The 2025 WAO guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities. World Allergy Organ J. 2026;19(5):101335. doi:10.1016/j.waojou.2026.101335